Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01401959
Title Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

breast cancer

Therapies

Eribulin

Eribulin + Trastuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.